类风湿关节炎中累积炎症、心脏危险因素与药物暴露对冠状动脉粥样硬化进展的影响
生物制剂、他汀及严格收缩压控制可能限制斑块进展。
要点
- 累积炎症是RA冠状动脉粥样硬化进展的独立预测因素
- 较长生物制剂暴露与较低非钙化斑块进展风险相关
- 他汀治疗和严格收缩压控制可减弱炎症对斑块进展的影响
核心结论
- 炎症是RA患者冠状动脉粥样硬化进展的一致且独立的预测因素,应针对性干预以降低心血管风险。
- 生物制剂改善病情抗风湿药、他汀和血压控制可能直接或间接限制斑块进展。
研究设计与样本
- 斑块负荷以节段受累评分和节段狭窄评分报告,斑块成分分为非钙化、混合或钙化,冠状动脉钙化(CAC)用Agatston法量化。
主要发现
- 48%的患者总斑块增加,进展由年龄较大、较高的累积炎症和泼尼松总剂量预测(P<0.05)。
- CAC进展者较非进展者年龄更大、更肥胖、高血压比例更高且累积炎症更高(P<0.05)。
- 较长的生物制剂暴露与较低的非钙化斑块进展、病变重塑及无基线钙化患者CAC变化受限的可能性相关,独立于炎症、泼尼松剂量或他汀暴露(所有P<0.05)。
- 较长的他汀治疗进一步限制非钙化斑块进展并减弱炎症对斑块增加和CAC的影响(P<0.05)。
- 严格的收缩压控制进一步减弱炎症对总斑块进展的影响。
关键数值与推荐
- 总斑块进展定义为随访期间总斑块增加,发生于48%的患者。
- 斑块负荷以节段受累评分(描述有斑块的冠状动脉节段数)和节段狭窄评分(表征所有可评估节段的累积斑块狭窄)报告。
- CAC采用Agatston法量化。
临床怎么用
- 在RA管理中应将炎症控制作为降低心血管风险的具体目标。
- 可考虑使用生物制剂、他汀和严格血压控制以限制冠状动脉斑块进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore incidence and progression of coronary atherosclerosis and identify determinants in patients with rheumatoid arthritis (RA). We specifically evaluated the impact of inflammation, cardiac risk factors, duration of medication exposure, and their interactions on coronary plaque progression. METHODS: One hundred one participants with baseline coronary computed tomography angiography findings underwent follow-up assessment a mean ± SD of 83 ± 3.6 months after baseline. Plaque burden was reported as the segment involvement score (describing the number of coronary segments with plaque) and the segment stenosis score (characterizing the cumulative plaque stenosis over all evaluable segments). Plaque composition was classified as noncalcified, mixed, or calcified. Coronary artery calcium (CAC) was quantified using the Agatston method. RESULTS: Total plaque increased in 48% of patients, and progression was predicted by older age, higher cumulative inflammation, and total prednisone dose (P < 0.05). CAC progressors were older, more obese, hypertensive, and had higher cumulative inflammation compared to nonprogressors (P < 0.05). Longer exposure to biologics was associated with lower likelihood of noncalcified plaque progression, lesion remodeling, and constrained CAC change in patients without baseline calcification, independent of inflammation, prednisone dose, or statin exposure (all P < 0.05). Longer statin treatment further restricted noncalcified plaque progression and attenuated the effect of inflammation on increased plaque and CAC (P < 0.05). Stringent systolic blood pressure (BP) control further weakened the effect of inflammation on total plaque progression. CONCLUSION: Inflammation was a consistent and independent predictor of coronary atherosclerosis progression in RA. It should therefore be specifically targeted toward mitigating cardiovascular risk. Biologic disease-modifying antirheumatic drugs, statins, and BP control may further constrain plaque progression directly or indirectly.
引用
- Karpouzas GA, Ormseth SR, Hernandez E, et al. Impact of Cumulative Inflammation, Cardiac Risk Factors, and Medication Exposure on Coronary Atherosclerosis Progression in Rheumatoid Arthritis. Arthritis Rheumatol. 2020. PMID: 31532064. doi:10.1002/art.41122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。